Filing Flows › Evofem Biosciences (EVFM) › Q1 2026 › vs Q4 2025
Evofem Biosciences (EVFM) Q1 2026 vs Q4 2025 (quarter over quarter)
Evofem Biosciences's revenue fell $8.7M (-91%) from $9.6M in Q4 2025 to $899K in Q1 2026.
Evofem Biosciences, Q1 2026: revenue $899K (+6% year over year), operating margin -508.2%, net loss $5.5M, operating cash flow $2.3M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 255.7% | 0.3% | +255.4 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $899K | $9.6M | −$8.7M | -91% |
| Income tax benefit | $1K | $1K | $0 | 0% |
| Net loss | $5.5M | −$2.8M | $8.3M | — |
| Costs & expenses | $6.4M | $9.6M | −$3.2M | -33% |
| Operating costs | $5.5M | $6.2M | −$748K | -12% |
| Interest & other, net | $897K | $558K | $339K | +61% |
| Cost of revenue | $410K | $2.6M | −$2.2M | -84% |
| Sales & marketing | $2.1M | $2.1M | $27K | +1% |
| General & admin | $2.4M | $1.1M | $1.3M | +116% |
| Other operating costs | $593K | $461K | $132K | +29% |
| Operating cash sources | $7.8M | −$2.8M | $10.5M | — |
| Depreciation & amortization | $79K | $94K | −$15K | -16% |
| Share-based compensation | $15K | $42K | −$27K | -64% |
| Working capital & other | $7.7M | −$2.9M | $10.6M | — |
| Net loss absorbed | $5.5M | −$2.8M | $8.3M | — |
| Operating cash flow | $2.3M | $31K | $2.3M | 74× |
| Free cash flow (OCF − capex) | $2.3M | $28K | $2.3M | 82× |
| Capital expenditures | $2K | $3K | −$1K | -33% |
Questions
How much did Evofem Biosciences's revenue grow quarter over quarter in Q1 2026?
Evofem Biosciences's revenue fell $8.7M (-91%) from $9.6M in Q4 2025 to $899K in Q1 2026.